Clinical value of thrombomodulin combined with thrombin-antithrombin complex for judging prognosis for sepsis

Objective　To determine the prognostic value of thrombomodulin (TM) combined with thrombinantithrombin complex (TAT) in patients with sepsis. Methods　A retrospective analysis of the clinical data from 80 patients with sepsis who met the inclusion and exclusion criteria admitted to the 908th Hospital of Chinese PLA Logistical Support Force from May 2018 to July 2019. The conventional coagulation tests, thromboelastographic (TEG) parameters, TM, TAT, α2-plasmin inhibitor-plasmin complex (PIC, namely plasmin/alpha 2-antiplasmin complex, PAP) and tissue plasminogen activator-inhibitor-1 complex (t-PAIC) were collected within 2 hours at admission. According to the prognosis of 90 days, the patients were divided into survival group and death group and statistical analysis were performed. Results　Compared with TM [11.7(8.8, 15.9) TU/ml] and TAT [11.3(7.0, 20.5) ng/ml] in the survival group, TM [20.2(14.1, 23.8) TU/ml] and TAT [17.7(11.8, 54.6) ng/ml] were significantly increased in the death group (P 16.95 TU/ml combined with TAT>10.55 ng/ml. Conclusion　TM combined with TAT can effectively judge the prognosis of sepsis patients and early identify sepsis related coagulation disorders. DOI: 10.11855/j.issn.0577-7402.2020.07.12